Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Apo-Quinapril (02248500), Apo-Quinapril (02248501), Apo-Quinapril (02248502). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

QUINAPRIL

8 general benefit · 4 not a benefit

Other products in the same Health Canada class (C09AA) — coverage varies; not interchangeable

  • Benazepril (Lotensin): general benefit, Not a benefit
  • Captopril (Noyada): general benefit, Limited Use 707, 723, Not a benefit
  • Cilazapril (Inhibace): general benefit, Not a benefit
  • Enalapril (Vasotec): general benefit, Not a benefit
  • Fosinopril (Monopril): general benefit, Not a benefit
  • Lisinopril (Prinivil): general benefit, Not a benefit

3 more in the class list below

Jamp Quinapril · DIN 02517450 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Quinapril · DIN 02517450 Manufacturer: Jamp Pharma Corporation; listing date 2024-01-31 Daily cost (source): $0.4642 Health Canada: Marketed since 2023-12-19 · brand JAMP QUINAPRIL · ATC C09AA06 QUINAPRIL · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 10 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Quinapril: Formulary list price $0.4642/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4642 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100684 · Verify on the e-Formulary ↗ (DIN 02517450)

Source record
DIN 02517450: Jamp Quinapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800161; group id 348; item number 0796; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4642; ministry $0.4642 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02517450 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100684
Interchangeable products
Accupril · DIN 01947672 · not recorded PMS-Quinapril · DIN 02340569 · $0.4642
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02517450
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Quinapril · DIN 02340569 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Quinapril · DIN 02340569 Manufacturer: Pharmascience Inc.; listing date 2019-11-29 Daily cost (source): $0.4642 Health Canada: Marketed since 2013-11-18 · brand PMS-QUINAPRIL · ATC C09AA06 QUINAPRIL · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 10 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Quinapril: Formulary list price $0.4642/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4642 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82614 · Verify on the e-Formulary ↗ (DIN 02340569)

Source record
DIN 02340569: PMS-Quinapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800161; group id 348; item number 0796; lccId None; manufacturer id PMS Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4642; ministry $0.4642 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02340569 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82614
Interchangeable products
Accupril · DIN 01947672 · not recorded Jamp Quinapril · DIN 02517450 · $0.4642
Shortage status: resolved shortage (ended 2025-04-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02340569
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Quinapril · DIN 02517469 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Quinapril · DIN 02517469 Manufacturer: Jamp Pharma Corporation; listing date 2024-01-31 Daily cost (source): $0.4642 Health Canada: Marketed since 2023-12-19 · brand JAMP QUINAPRIL · ATC C09AA06 QUINAPRIL · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 20 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Quinapril: Formulary list price $0.4642/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4642 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100685 · Verify on the e-Formulary ↗ (DIN 02517469)

Source record
DIN 02517469: Jamp Quinapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800162; group id 348; item number 0797; lccId None; manufacturer id JPC Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4642; ministry $0.4642 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02517469 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100685
Interchangeable products
Accupril · DIN 01947680 · not recorded PMS-Quinapril · DIN 02340577 · $0.4642
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02517469
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Quinapril · DIN 02340577 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Quinapril · DIN 02340577 Manufacturer: Pharmascience Inc.; listing date 2019-11-29 Daily cost (source): $0.4642 Health Canada: Marketed since 2013-11-18 · brand PMS-QUINAPRIL · ATC C09AA06 QUINAPRIL · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 20 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Quinapril: Formulary list price $0.4642/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4642 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82615 · Verify on the e-Formulary ↗ (DIN 02340577)

Source record
DIN 02340577: PMS-Quinapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800162; group id 348; item number 0797; lccId None; manufacturer id PMS Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4642; ministry $0.4642 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02340577 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82615
Interchangeable products
Accupril · DIN 01947680 · not recorded Jamp Quinapril · DIN 02517469 · $0.4642
Shortage status: resolved shortage (ended 2026-03-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02340577
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Quinapril · DIN 02517477 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Quinapril · DIN 02517477 Manufacturer: Jamp Pharma Corporation; listing date 2024-01-31 Daily cost (source): $0.4642 Health Canada: Marketed since 2023-12-19 · brand JAMP QUINAPRIL · ATC C09AA06 QUINAPRIL · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 40 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Quinapril: Formulary list price $0.4642/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4642 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100686 · Verify on the e-Formulary ↗ (DIN 02517477)

Source record
DIN 02517477: Jamp Quinapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800163; group id 348; item number 0798; lccId None; manufacturer id JPC Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4642; ministry $0.4642 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02517477 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100686
Interchangeable products
Accupril · DIN 01947699 · not recorded PMS-Quinapril · DIN 02340585 · $0.4642
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02517477
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Quinapril · DIN 02340585 · 40mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Quinapril · DIN 02340585 Manufacturer: Pharmascience Inc.; listing date 2019-11-29 Daily cost (source): $0.4642 Health Canada: Marketed since 2013-11-18 · brand PMS-QUINAPRIL · ATC C09AA06 QUINAPRIL · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 40 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Quinapril: Formulary list price $0.4642/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4642 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82616 · Verify on the e-Formulary ↗ (DIN 02340585)

Source record
DIN 02340585: PMS-Quinapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800163; group id 348; item number 0798; lccId None; manufacturer id PMS Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4642; ministry $0.4642 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02340585 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82616
Interchangeable products
Accupril · DIN 01947699 · not recorded Jamp Quinapril · DIN 02517477 · $0.4642
Shortage status: resolved shortage (ended 2026-03-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02340585
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Quinapril · DIN 02248499 · 5mg · tablet

General benefitDormant since 2022-04-10 · checked 2026-09-02 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Quinapril · DIN 02248499 Manufacturer: Apotex Inc.; listing date 2013-10-31 Daily cost (source): $0.4642 Health Canada: Dormant since 2022-04-10 · brand APO-QUINAPRIL · ATC C09AA06 QUINAPRIL · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Quinapril: Formulary list price $0.4642/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4642 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72851 · Verify on the e-Formulary ↗ (DIN 02248499)

Source record
DIN 02248499: Apo-Quinapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800160; group id 348; item number 0795; lccId None; manufacturer id APX Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4642; ministry $0.4642 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248499 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72851
Interchangeable products
Accupril · DIN 01947664 · not recorded PMS-Quinapril · DIN 02340550 · $0.4642
Shortage status: active shortage (reported 2021-03-09, last updated 2021-10-29) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248499
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2022-04-10 — choose a marketed DIN from the same-category list.

PMS-Quinapril · DIN 02340550 · 5mg · tablet

General benefitDormant since 2025-08-01 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Quinapril · DIN 02340550 Manufacturer: Pharmascience Inc.; listing date 2019-11-29 Daily cost (source): $0.4642 Health Canada: Dormant since 2025-08-01 · brand PMS-QUINAPRIL · ATC C09AA06 QUINAPRIL · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Quinapril: Formulary list price $0.4642/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4642 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82613 · Verify on the e-Formulary ↗ (DIN 02340550)

Source record
DIN 02340550: PMS-Quinapril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800160; group id 348; item number 0795; lccId None; manufacturer id PMS Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4642; ministry $0.4642 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02340550 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82613
Interchangeable products
Accupril · DIN 01947664 · not recorded Apo-Quinapril · DIN 02248499 · $0.4642
Shortage status: resolved shortage (ended 2026-01-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02340550
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-08-01 — choose a marketed DIN from the same-category list.

Accupril · DIN 01947664 · 5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.Discontinued 2024-04-05 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Accupril · DIN 01947664 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Daily cost (source): $0.4642 Health Canada: Cancelled post market since 2024-04-05 · brand ACCUPRIL 5MG TAB · ATC C09AA06 QUINAPRIL · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 5 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Accupril: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12331 · Verify on the e-Formulary ↗ (DIN 01947664)

Source record
DIN 01947664: Accupril Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800160; group id 348; item number 0795; lccId None; manufacturer id PFI Source form: Tab; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01947664 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12331
Interchangeable products
Apo-Quinapril · DIN 02248499 · $0.4642 PMS-Quinapril · DIN 02340550 · $0.4642
Shortage status: active shortage (reported 2021-09-30, last updated 2022-04-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01947664
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.

Accupril · DIN 01947672 · 10mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.Discontinued 2024-04-05 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Accupril · DIN 01947672 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Daily cost (source): $0.4642 Health Canada: Cancelled post market since 2024-04-05 · brand ACCUPRIL TAB 10MG · ATC C09AA06 QUINAPRIL · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 10 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Accupril: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12332 · Verify on the e-Formulary ↗ (DIN 01947672)

Source record
DIN 01947672: Accupril Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800161; group id 348; item number 0796; lccId None; manufacturer id PFI Source form: Tab; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01947672 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12332
Interchangeable products
Jamp Quinapril · DIN 02517450 · $0.4642 PMS-Quinapril · DIN 02340569 · $0.4642
Shortage status: active shortage (reported 2022-04-19, last updated 2022-04-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01947672
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.

Accupril · DIN 01947680 · 20mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.Discontinued 2024-04-05 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Accupril · DIN 01947680 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Daily cost (source): $0.4642 Health Canada: Cancelled post market since 2024-04-05 · brand ACCUPRIL TAB 20MG · ATC C09AA06 QUINAPRIL · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 20 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Accupril: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12333 · Verify on the e-Formulary ↗ (DIN 01947680)

Source record
DIN 01947680: Accupril Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800162; group id 348; item number 0797; lccId None; manufacturer id PFI Source form: Tab; strength: 20mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01947680 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12333
Interchangeable products
Jamp Quinapril · DIN 02517469 · $0.4642 PMS-Quinapril · DIN 02340577 · $0.4642
Shortage status: active shortage (reported 2022-04-19, last updated 2022-04-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01947680
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.

Accupril · DIN 01947699 · 40mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.Discontinued 2024-04-05 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Accupril · DIN 01947699 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Daily cost (source): $0.4642 Health Canada: Cancelled post market since 2024-04-05 · brand ACCUPRIL TAB 40MG · ATC C09AA06 QUINAPRIL · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 40 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Accupril: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12334 · Verify on the e-Formulary ↗ (DIN 01947699)

Source record
DIN 01947699: Accupril Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800163; group id 348; item number 0798; lccId None; manufacturer id PFI Source form: Tab; strength: 40mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01947699 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12334
Interchangeable products
Jamp Quinapril · DIN 02517477 · $0.4642 PMS-Quinapril · DIN 02340585 · $0.4642
Shortage status: active shortage (reported 2022-04-19, last updated 2022-04-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01947699
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.

QUINAPRIL & HYDROCHLOROTHIAZIDE

8 general benefit · 3 not a benefit

Other products in the same Health Canada class (C09AA) — coverage varies; not interchangeable

  • Benazepril (Lotensin): general benefit, Not a benefit
  • Captopril (Noyada): general benefit, Limited Use 707, 723, Not a benefit
  • Cilazapril (Inhibace): general benefit, Not a benefit
  • Enalapril (Vasotec): general benefit, Not a benefit
  • Fosinopril (Monopril): general benefit, Not a benefit
  • Lisinopril (Prinivil): general benefit, Not a benefit

3 more in the class list below

Apo-Quinapril/HCTZ · DIN 02408767 · 10mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Quinapril/HCTZ · DIN 02408767 Manufacturer: Apotex Inc.; listing date 2013-10-31 Health Canada: Marketed since 2025-06-16 · brand APO-QUINAPRIL/HCTZ · ATC C09BA06 QUINAPRIL AND DIURETICS, C09BA06 QUINAPRIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 10 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Quinapril/HCTZ: Formulary list price $0.2393/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2393 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89352 · Verify on the e-Formulary ↗ (DIN 02408767)

Source record
DIN 02408767: Apo-Quinapril/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800239; group id 349; item number 0799; lccId None; manufacturer id APX Source form: Tab; strength: 10mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2393; ministry $0.2393 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02408767 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89352
Interchangeable products
Accuretic · DIN 02237367 · not recorded Auro-Quinapril HCTZ · DIN 02473291 · $0.2393 Jamp Quinapril / HCTZ · DIN 02547430 · $0.2393
Shortage status: resolved shortage (ended 2025-07-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02408767
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Quinapril HCTZ · DIN 02473291 · 10mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Quinapril HCTZ · DIN 02473291 Manufacturer: Auro Pharma Inc.; listing date 2019-03-28 Health Canada: Marketed since 2019-02-01 · brand AURO-QUINAPRIL HCTZ · ATC C09BA06 QUINAPRIL AND DIURETICS, C09BA06 QUINAPRIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 10 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Quinapril HCTZ: Formulary list price $0.2393/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2393 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96270 · Verify on the e-Formulary ↗ (DIN 02473291)

Source record
DIN 02473291: Auro-Quinapril HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800239; group id 349; item number 0799; lccId None; manufacturer id AUR Source form: Tab; strength: 10mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2393; ministry $0.2393 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02473291 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96270
Interchangeable products
Accuretic · DIN 02237367 · not recorded Apo-Quinapril/HCTZ · DIN 02408767 · $0.2393 Jamp Quinapril / HCTZ · DIN 02547430 · $0.2393
Shortage status: resolved shortage (ended 2025-07-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02473291
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Quinapril / HCTZ · DIN 02547430 · 10mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Quinapril / HCTZ · DIN 02547430 Manufacturer: Jamp Pharma Corporation; listing date 2025-06-30 Health Canada: Marketed since 2025-03-18 · brand JAMP QUINAPRIL / HCTZ · ATC C09BA06 QUINAPRIL AND DIURETICS, C09BA06 QUINAPRIL AND DIURETICS · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 10 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Quinapril / HCTZ: Formulary list price $0.2393/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2393 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103639 · Verify on the e-Formulary ↗ (DIN 02547430)

Source record
DIN 02547430: Jamp Quinapril / HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800239; group id 349; item number 0799; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2393; ministry $0.2393 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02547430 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103639
Interchangeable products
Accuretic · DIN 02237367 · not recorded Apo-Quinapril/HCTZ · DIN 02408767 · $0.2393 Auro-Quinapril HCTZ · DIN 02473291 · $0.2393
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02547430
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Quinapril/HCTZ · DIN 02408775 · 20mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Quinapril/HCTZ · DIN 02408775 Manufacturer: Apotex Inc.; listing date 2013-10-31 Health Canada: Marketed since 2025-06-16 · brand APO-QUINAPRIL/HCTZ · ATC C09BA06 QUINAPRIL AND DIURETICS, C09BA06 QUINAPRIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 20 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Quinapril/HCTZ: Formulary list price $0.4786/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4786 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89353 · Verify on the e-Formulary ↗ (DIN 02408775)

Source record
DIN 02408775: Apo-Quinapril/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800240; group id 349; item number 0800; lccId None; manufacturer id APX Source form: Tab; strength: 20mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4786; ministry $0.4786 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02408775 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89353
Interchangeable products
Accuretic · DIN 02237368 · not recorded Auro-Quinapril HCTZ · DIN 02473305 · $0.4786
Shortage status: resolved shortage (ended 2025-07-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02408775
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Quinapril/HCTZ · DIN 02408783 · 20mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Quinapril/HCTZ · DIN 02408783 Manufacturer: Apotex Inc.; listing date 2013-10-31 Health Canada: Marketed since 2025-06-16 · brand APO-QUINAPRIL/HCTZ · ATC C09BA06 QUINAPRIL AND DIURETICS, C09BA06 QUINAPRIL AND DIURETICS · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 20 MG, HYDROCHLOROTHIAZIDE 25 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Quinapril/HCTZ: Formulary list price $0.2301/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2301 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89354 · Verify on the e-Formulary ↗ (DIN 02408783)

Source record
DIN 02408783: Apo-Quinapril/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800256; group id 349; item number 0801; lccId None; manufacturer id APX Source form: Tab; strength: 20mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2301; ministry $0.2301 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02408783 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89354
Interchangeable products
Accuretic · DIN 02237369 · not recorded Auro-Quinapril HCTZ · DIN 02473321 · $0.2301 Jamp Quinapril / HCTZ · DIN 02547449 · $0.2301
Shortage status: resolved shortage (ended 2025-07-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02408783
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Quinapril HCTZ · DIN 02473305 · 20mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Quinapril HCTZ · DIN 02473305 Manufacturer: Auro Pharma Inc.; listing date 2019-03-28 Health Canada: Marketed since 2019-02-01 · brand AURO-QUINAPRIL HCTZ · ATC C09BA06 QUINAPRIL AND DIURETICS, C09BA06 QUINAPRIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 20 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Quinapril HCTZ: Formulary list price $0.4786/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4786 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96271 · Verify on the e-Formulary ↗ (DIN 02473305)

Source record
DIN 02473305: Auro-Quinapril HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800240; group id 349; item number 0800; lccId None; manufacturer id AUR Source form: Tab; strength: 20mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4786; ministry $0.4786 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02473305 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96271
Interchangeable products
Accuretic · DIN 02237368 · not recorded Apo-Quinapril/HCTZ · DIN 02408775 · $0.4786
Shortage status: resolved shortage (ended 2025-07-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02473305
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Quinapril HCTZ · DIN 02473321 · 20mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Quinapril HCTZ · DIN 02473321 Manufacturer: Auro Pharma Inc.; listing date 2019-03-28 Health Canada: Marketed since 2019-02-01 · brand AURO-QUINAPRIL HCTZ · ATC C09BA06 QUINAPRIL AND DIURETICS, C09BA06 QUINAPRIL AND DIURETICS · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 20 MG, HYDROCHLOROTHIAZIDE 25 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Quinapril HCTZ: Formulary list price $0.2301/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2301 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96273 · Verify on the e-Formulary ↗ (DIN 02473321)

Source record
DIN 02473321: Auro-Quinapril HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800256; group id 349; item number 0801; lccId None; manufacturer id AUR Source form: Tab; strength: 20mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2301; ministry $0.2301 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02473321 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96273
Interchangeable products
Accuretic · DIN 02237369 · not recorded Apo-Quinapril/HCTZ · DIN 02408783 · $0.2301 Jamp Quinapril / HCTZ · DIN 02547449 · $0.2301
Shortage status: resolved shortage (ended 2025-07-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02473321
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Quinapril / HCTZ · DIN 02547449 · 20mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Quinapril / HCTZ · DIN 02547449 Manufacturer: Jamp Pharma Corporation; listing date 2025-06-30 Health Canada: Marketed since 2025-03-18 · brand JAMP QUINAPRIL / HCTZ · ATC C09BA06 QUINAPRIL AND DIURETICS, C09BA06 QUINAPRIL AND DIURETICS · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 20 MG, HYDROCHLOROTHIAZIDE 25 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Quinapril / HCTZ: Formulary list price $0.2301/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2301 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103640 · Verify on the e-Formulary ↗ (DIN 02547449)

Source record
DIN 02547449: Jamp Quinapril / HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800256; group id 349; item number 0801; lccId None; manufacturer id JPC Source form: Tab; strength: 20mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2301; ministry $0.2301 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02547449 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103640
Interchangeable products
Accuretic · DIN 02237369 · not recorded Apo-Quinapril/HCTZ · DIN 02408783 · $0.2301 Auro-Quinapril HCTZ · DIN 02473321 · $0.2301
Shortage status: active shortage (reported 2026-06-30, estimated to end 2026-08-14, last updated 2026-07-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02547449
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Accuretic · DIN 02237367 · 10mg & 12.5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.Discontinued 2024-04-05 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Accuretic · DIN 02237367 Manufacturer: Pfizer Canada Inc.; listing date 2000-07-17 Health Canada: Cancelled post market since 2024-04-05 · brand ACCURETIC · ATC C09BA06 QUINAPRIL AND DIURETICS, C09BA06 QUINAPRIL AND DIURETICS · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 10 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Accuretic: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60690 · Verify on the e-Formulary ↗ (DIN 02237367)

Source record
DIN 02237367: Accuretic Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800239; group id 349; item number 0799; lccId None; manufacturer id PFI Source form: Tab; strength: 10mg & 12.5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237367 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60690
Interchangeable products
Apo-Quinapril/HCTZ · DIN 02408767 · $0.2393 Auro-Quinapril HCTZ · DIN 02473291 · $0.2393 Jamp Quinapril / HCTZ · DIN 02547430 · $0.2393
Shortage status: active shortage (reported 2022-03-01, last updated 2022-03-02) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237367
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.

Accuretic · DIN 02237368 · 20mg & 12.5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.Discontinued 2024-04-05 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Accuretic · DIN 02237368 Manufacturer: Pfizer Canada Inc.; listing date 2000-07-17 Health Canada: Cancelled post market since 2024-04-05 · brand ACCURETIC · ATC C09BA06 QUINAPRIL AND DIURETICS, C09BA06 QUINAPRIL AND DIURETICS · form Tablet · route Oral · ingredients QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 20 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Accuretic: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60691 · Verify on the e-Formulary ↗ (DIN 02237368)

Source record
DIN 02237368: Accuretic Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800240; group id 349; item number 0800; lccId None; manufacturer id PFI Source form: Tab; strength: 20mg & 12.5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237368 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60691
Interchangeable products
Apo-Quinapril/HCTZ · DIN 02408775 · $0.4786 Auro-Quinapril HCTZ · DIN 02473305 · $0.4786
Shortage status: active shortage (reported 2022-03-01, last updated 2022-03-02) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237368
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.

Accuretic · DIN 02237369 · 20mg & 25mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.Discontinued 2024-04-05 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Accuretic · DIN 02237369 Manufacturer: Pfizer Canada Inc.; listing date 2004-04-06 Health Canada: Cancelled post market since 2024-04-05 · brand ACCURETIC · ATC C09BA06 QUINAPRIL AND DIURETICS, C09BA06 QUINAPRIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 20 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Accuretic: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60692 · Verify on the e-Formulary ↗ (DIN 02237369)

Source record
DIN 02237369: Accuretic Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800256; group id 349; item number 0801; lccId None; manufacturer id PFI Source form: Tab; strength: 20mg & 25mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237369 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60692
Interchangeable products
Apo-Quinapril/HCTZ · DIN 02408783 · $0.2301 Auro-Quinapril HCTZ · DIN 02473321 · $0.2301 Jamp Quinapril / HCTZ · DIN 02547449 · $0.2301
Shortage status: active shortage (reported 2022-03-01, last updated 2022-03-02) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237369
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2024-04-05 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab

LISINOPRIL

· 45 products · Listed, not a benefit (1), General benefit (44) · strengths: 5mg, 10mg, 20mg · Tab

PERINDOPRIL ERBUMINE

· 45 products · General benefit · strengths: 2mg, 4mg, 8mg · Tab

RAMIPRIL

· 67 products · General benefit (57), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.25mg, 2.5mg, 5mg, 10mg, 15mg · Cap

TRANDOLAPRIL

· 26 products · Off-Formulary Interchangeable, not an ODB benefit (5), General benefit (21) · strengths: 0.5mg, 1mg, 2mg, 4mg · Cap

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 34 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6) INDICATIONS AND CLINICAL USE APO-ACEBUTOLOL is indicated for the following:  Treatment of mild to moderate hypertension.  Long-term management of patients with angina pectoris due to ischemic heart disease. PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10 Product monograph AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) 1 INDICATIONS NORVASC (amlodipine besylate tablets) is indicated for: • Hypertension NORVASC is indicated in the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10 Product monograph AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit 1 Part 1: Healthcare Professional Information Indications • EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10 Product monograph BENAZEPRIL · Listed, not a benefit (3), General benefit (3) Indications BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:  Treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL · General benefit • Heart Failure o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in addition to standard therapy, with or without an ACE inhibitor. 1.1 Pediatrics Pediatrics (6 to 17 years of age): • Hypertension ATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph • Hypertension PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for: • the treatment of essential hypertension in patients for whom combination therapy is appropriate. PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10 Product monograph CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2) 1 INDICATIONS APO-CHLORTHALIDONE (chlorthalidone) is indicated for: • Treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10 Product monograph CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:  treatment of mild to moderate essential hypertension in patients for whom combination therapy with both cilazapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10 Product monograph CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) INDICATIONS AND CLINICAL USE TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10 Product monograph ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:  Treatment of essential hypertension in patients for whom this combination therapy with enalapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10 Product monograph and 19 more Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS pms-QUINAPRIL (quinapril tablets) is indicated for: • Hypertension: treatment of essential hypertension. It is usually administered in association with other drugs, particularly thiazide diuretics. • Congestive Heart Failure: treatment of congestive heart failure as adjunctive therapy when added to diuretics and/or digitalis glycosides. The safety and efficacy of quinapril tablets in renovascular hypertension has not been established; therefore, use in this condition is not recommended. Treatment with pms-QUINAPRIL should be initiated under close medical supervision. 1.1 Pediatrics (<18 years of age) Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics (> 65 years of age) Of the total number of subjects in clinical studies of quinapril tablets, 21% were ≥65 years old. (There was no distinction between patients >65 or >75 years.) No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience did not identify differences in responses b… https://pdf.hres.ca/dpd_pm/00071767.PDF PM date: NOV 15, 2013 Source product: PMS-QUINAPRIL; DIN 02340569; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS APO-QUINAPRIL/HCTZ (quinapril hydrochloride and hydrochlorothiazide) is indicated for the treatment of essential hypertension in patients for whom combination therapy is appropriate. APO-QUINAPRIL/HCTZ is not indicated for initial therapy. Patients in whom quinapril and hydrochlorothiazide are initiated simultaneously can develop symptomatic hypotension (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular, - Hypotension and 9 DRUG INTERACTIONS). Patients should be titrated on the individual drugs. If the fixed combination represents the dosage determined by this titration, the use of APO-QUINAPRIL/HCTZ may be more convenient in the management of patients. If during maintenance therapy dosage adjustment is necessary, it is advisable to use individual drugs. 1.1 Pediatrics (<18 years of age) Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics (> 65 years of age) Therapeutic effects appear to be the same for elderly (>65 years of age) and younger adult patients given the same daily dosages, with no increase in adverse events in elderly pa… https://pdf.hres.ca/dpd_pm/00074827.PDF PM date: MAR 05, 2024 Source product: APO-QUINAPRIL/HCTZ; DIN 02408767; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Quinapril · DIN 02248499 Shortage status: active shortage (reported 2021-03-09, last updated 2021-10-29) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248499

Check this DIN again

Accupril · DIN 01947664 Shortage status: active shortage (reported 2021-09-30, last updated 2022-04-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01947664

Check this DIN again

Accupril · DIN 01947672 Shortage status: active shortage (reported 2022-04-19, last updated 2022-04-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01947672

Check this DIN again

Accupril · DIN 01947680 Shortage status: active shortage (reported 2022-04-19, last updated 2022-04-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01947680

Check this DIN again

Accupril · DIN 01947699 Shortage status: active shortage (reported 2022-04-19, last updated 2022-04-20) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01947699

Check this DIN again

Jamp Quinapril / HCTZ · DIN 02547449 Shortage status: active shortage (reported 2026-06-30, estimated to end 2026-08-14, last updated 2026-07-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02547449

Check this DIN again

Accuretic · DIN 02237367 Shortage status: active shortage (reported 2022-03-01, last updated 2022-03-02) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237367

Check this DIN again

Accuretic · DIN 02237368 Shortage status: active shortage (reported 2022-03-01, last updated 2022-03-02) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237368

Check this DIN again

Accuretic · DIN 02237369 Shortage status: active shortage (reported 2022-03-01, last updated 2022-03-02) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237369

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Accupril, Accuretic: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026